[go: up one dir, main page]

WO1998011920A3 - Method of capture of a bioactive agent by a nanoerythrosome preparation - Google Patents

Method of capture of a bioactive agent by a nanoerythrosome preparation Download PDF

Info

Publication number
WO1998011920A3
WO1998011920A3 PCT/CA1997/000699 CA9700699W WO9811920A3 WO 1998011920 A3 WO1998011920 A3 WO 1998011920A3 CA 9700699 W CA9700699 W CA 9700699W WO 9811920 A3 WO9811920 A3 WO 9811920A3
Authority
WO
WIPO (PCT)
Prior art keywords
nanoerythrosome
present
relates
bioactive agent
capture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1997/000699
Other languages
French (fr)
Other versions
WO1998011920A2 (en
Inventor
Rene Gaudreault
Claude Gicquaud
Patrick Poyet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnocure Inc
Original Assignee
Diagnocure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnocure Inc filed Critical Diagnocure Inc
Priority to AU43733/97A priority Critical patent/AU4373397A/en
Publication of WO1998011920A2 publication Critical patent/WO1998011920A2/en
Publication of WO1998011920A3 publication Critical patent/WO1998011920A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to nanoErythrosomes, a Drug Delivery System (DDS). More specifically, the present invention relates a new method of entrapping/capturing a bioactive agent in the nanoErythrosomes. Moreover, the present invention relates to nanoErythrosome compositions in diagnostic and therapeutic methods. The invention further relates to the bioassays using the nanoErythrosome composition of the present invention to diagnose or prognose a predetermined condition in an animal, as well as kits containing those nanoErythrosome compositions.
PCT/CA1997/000699 1996-09-19 1997-09-19 Method of capture of a bioactive agent by a nanoerythrosome preparation Ceased WO1998011920A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU43733/97A AU4373397A (en) 1996-09-19 1997-09-19 Method of capture of a bioactive agent by a nanoerythrosome preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2636396P 1996-09-19 1996-09-19
US60/026,363 1996-09-19

Publications (2)

Publication Number Publication Date
WO1998011920A2 WO1998011920A2 (en) 1998-03-26
WO1998011920A3 true WO1998011920A3 (en) 1998-05-22

Family

ID=21831380

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CA1997/000698 Ceased WO1998011919A2 (en) 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof
PCT/CA1997/000699 Ceased WO1998011920A2 (en) 1996-09-19 1997-09-19 Method of capture of a bioactive agent by a nanoerythrosome preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000698 Ceased WO1998011919A2 (en) 1996-09-19 1997-09-19 Polyethyleneglycol conjugated nanoerythrosomes, method of making same and use thereof

Country Status (5)

Country Link
EP (1) EP0929317A2 (en)
JP (1) JP2001501190A (en)
AU (2) AU4373397A (en)
CA (1) CA2266388A1 (en)
WO (2) WO1998011919A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10000838B4 (en) * 2000-01-12 2005-03-17 Schott Ag Alkali-free aluminoborosilicate glass and its uses
EP1403639A1 (en) * 2002-09-30 2004-03-31 G2M Cancer Drugs AG Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
AU2003300133B2 (en) 2002-12-31 2008-11-13 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP2015071A1 (en) * 2007-07-13 2009-01-14 FUJIFILM Corporation Carrier, process for producing same, bioreactor, and chip for surface plasmon resonance analysis
US20130202625A1 (en) * 2010-01-21 2013-08-08 The Regents Of The University Of Californa Use of human erythrocytes for prevention and treatment of cancer dissemination and growth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653999A (en) * 1995-02-07 1997-08-05 Universite Laval Nanoerythrosome as bioactive agent carrier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653999A (en) * 1995-02-07 1997-08-05 Universite Laval Nanoerythrosome as bioactive agent carrier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GULEVSKII A.K. ET AL.: "ROLE OF DEHYDRATATION IN CHANGING THE PERMEABILITY OF ERYTHROCYTE PLASMA MEMBRANES BY FREEZE-THAWING.", BIOCHIM. BIOPHYS. ACTA, vol. 728, no. 3, 1983, pages 371 - 376, XP002060492 *
MOORJANI M. ET AL.: "PREPARATION AND USE OF NANO-ERYTHROSOMES AS A DRUG CARRIER FOR DAUNORUBICIN", PROC. ANN. MEET. AM. ASSOC. CANCER RES., vol. 35, March 1994 (1994-03-01), pages 415, XP002060493 *

Also Published As

Publication number Publication date
WO1998011919A3 (en) 1998-06-04
WO1998011919A2 (en) 1998-03-26
WO1998011920A2 (en) 1998-03-26
EP0929317A2 (en) 1999-07-21
JP2001501190A (en) 2001-01-30
AU4373297A (en) 1998-04-14
AU4373397A (en) 1998-04-14
CA2266388A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
CA2151560A1 (en) Insulin Analog Formulations
EP0771788A3 (en) Substituted sulphonimidamides, method for their preparation, their use as medicament or diagnostic and medicament containing them
IT1241996B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
EP0841936A4 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
DE69731659D1 (en) Vaccine preparation consisting of sub-units of the respiratory synergy virus (RSV)
NO902441D0 (en) Aroma delivery system, as well as chewing gum mixture.
FR2771291B1 (en) SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS
ES8705200A1 (en) A chewing gum composition and method for the preparation thereof.
EP0693285A3 (en) Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss
CA2232001A1 (en) Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
DE69530308D1 (en) METHOD FOR PRODUCING DOSING FORMS BY MOISTURIZING
IE841423L (en) Antidiabetic composition
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
CA2280310A1 (en) Nmda antagonist
IT1241997B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISORDERS AND METHOD FOR ITS APPLICATION.
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
WO1998011920A3 (en) Method of capture of a bioactive agent by a nanoerythrosome preparation
FR2771292B1 (en) TIAGABINE-CONTAINING SPHEROIDS, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS
ZA964035B (en) Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
GR3032363T3 (en) Substituted cinnamic acid guanidides, process for their preparation, their use as cardiovascualr medicament or diagnostic agent, as well as medicament containing them
WO1999014345A3 (en) Medicament for treating a manifested lyme disease
ZA974665B (en) Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
CY2220B1 (en) Substituted benzenesulfonylureas and -thioureas process for their preparation their use as medicament or diagnostic agent as well as medicaments containing them
CA2071837A1 (en) Vitamin-Mineral Treatment Methods and Compositions
HRP970424B1 (en) Substituted indanylidineacetylguanidines, process for their preparation, their use as medicaments or diagnostic agents and medicaments containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV GH

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998514111

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA